Results 171 to 180 of about 607,524 (301)

Tasurgratinib (E7090) for cholangiocarcinoma with fibroblast growth factor receptor 2 fusions/rearrangements: a multicenter, open-label, Phase 2 study. [PDF]

Jpn J Clin Oncol
Shen L, Duan H, Kuwahara T, Satoh T, Ma X, Yan S, Zhao H, Ikeda M, Cui T, Sasaki T, Meng Z, Nakai Y, Ueno M, Komatsu Y, Nagano H, Morizane C, Funasaka S, Ikezawa H, Nakada T, Furuse J.   +19 more
europepmc   +1 more source

TSPYL5 Promotes Triple‐Negative Breast Cancer Metastasis by Antagonizing USP10‐Mediated PTEN Stabilization to Unleash a ZEB1‐Dependent EMT Program

Advanced Science, EarlyView.
The hyperactivation of PI3K/AKT signaling in PTEN wild‐type triple‐negative breast cancer represents a clinical paradox. We delineate a novel post‐translational regulatory axis wherein the oncogene TSPYL5 competitively antagonizes the deubiquitinase USP10.
Jiaying Shi, Ming Yi, Shengyu Xie, Zhaokun Wang, Xinyue Zhang, Yangwei Zhang, Rui Tang, Yuan Yang, Yunqiang Liu   +8 more
wiley   +1 more source

A single-institution study of the natural history of fibroblast growth factor receptor-altered gliomas. [PDF]

Neurooncol Pract
Viera M, Mount CW, Dias-Santagata D, Miller JJ, Gerstner ER.   +4 more
europepmc   +1 more source

m6A‐Mediated Glycolysis by IL‐37 Drives T Cell Metabolic Reprogramming to Regulate Colitis

Advanced Science, EarlyView.
This study identifies an IL‐37/SIGIRR‐METTL14 regulatory axis that suppresses global m6A modification in CD4+ T cells. IL‐37 signaling, mediated through SIGIRR, inhibits IRAK4 and JNK phosphorylation, leading to downregulation of the methyltransferase METTL14.
Xiaoyan Wang, Jiadong Yu, Guolin Li, Ya Li, Fanlian Zeng, Jing Hu, Yifan Zhou, Chengcheng Yue, Qixiang Zhao, Chen Zhang, Hong Zhou, Fulei Zhao, Yawen Hu, Pei Zhou, Linna Gu, Yuting Feng, Mingxiang He, Shishi Huang, Xiaochi Sun, Xinmeng Wang, Jie Tang, Xinyu Zeng, Wenling Wu, Nongyu Huang, Xinai Cui, Kaijun Cui, Jiong Li   +26 more
wiley   +1 more source

Uralenol, Glycyrol, and Abyssinone II as potent inhibitors of fibroblast growth factor receptor 2 from anti-cancer plants: A deep learning and molecular dynamics approach. [PDF]

PLoS One
Hossain A, Hossan MS, Prodhan MS, Joy MNH, Siam MR, Rahman ME, Matin MN.   +6 more
europepmc   +1 more source

Engineering Immunoregenerative Therapy via an Immunomodulatory Binary Pharmacology Hydrogel Depot for Prolonged Allograft Survival

Advanced Science, EarlyView.
An immunomodulatory hydrogel (iGEL) forms spontaneously upon subcutaneous injection, acting as a tissue‐adhesive depot. It releases anti‐rejection and regenerative agents in response to inflammation, suppressing T‐cell activity, promoting vascular repair, and restoring allograft function without systemic immunosuppression.
Ning Wang, Ruiqi Sun, Yang Fu, Zhonghan Wu, Xinyu Tong, Hong Tang, Wentao Zhao, Zhi Liang, Jintao Zheng, Yanan Guan, Ke Zhou, Penghong Song, Shusen Zheng, Hangxiang Wang, Haiyang Xie   +14 more
wiley   +1 more source

The Role of Fibroblast Growth Factor Receptor 2 as A Prognostic Biomarker in Colorectal Adenocarcinoma. [PDF]

Asian Pac J Cancer Prev
Rianti AM, Miskad UA, Cangara MH, Wahid S, Achmad D, Tawali S.   +5 more
europepmc   +1 more source

FGF13 Deficiency Ameliorates Paclitaxel‐Induced Neuropathic Pain by Inhibiting VASH1‐Mediated Microtubule Detyrosination to Promote Mitophagy

Advanced Science, EarlyView.
FGF13 is upregulated in DRG neurons of PIPNP model mice. DRG neuron‐specific knockout of FGF13 ameliorates PIPNP symptoms. Mechanistically, FGF13 potentiates microtubule detyrosination by promoting VASH1 binding to microtubules. FGF13 knockout suppresses VASH1‐mediated microtubule detyrosination and promotes α‐tubulin tyrosination.
Yiming Dong, Yidan Wang, Simeng Lv, Zishan Dong, Kaixi Zhi, Xiuhua Guo, Xuyan Li, Ruoxi Yu, Yiyi Zhang, Siyuan Cheng, Chuan Wang   +10 more
wiley   +1 more source

Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea

Proceedings of the National Academy of Sciences of the United States of America, 2002
H. Kubo, R. Cao, Ebba Bräkenhielm, Taija Mäkinen, Yihai Cao, K. Alitalo   +5 more
semanticscholar   +1 more source

Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results. [PDF]

Oncologist
Spanggaard I, Matrana M, Rocha Lima C, Mahipal A, Vieito M, Hervieu A, Goyal L, Rodón J, Veronese ML, Oliveira N, Li X, Schaffer M, Kesari S.   +12 more
europepmc   +1 more source